GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Australian Clinical Labs Ltd (ASX:ACL) » Definitions » GF Value

Australian Clinical Labs (ASX:ACL) GF Value : A$2.86 (As of Mar. 28, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Australian Clinical Labs GF Value?

As of today (2025-03-28), Australian Clinical Labs's share price is A$2.97. Australian Clinical Labs's GF Value is A$2.86. Therefore, Australian Clinical Labs's Price-to-GF-Value for today is 1.04. Based on the relationship between the current stock price and the GF Value, GuruFocus believes Australian Clinical Labs is Fairly Valued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

  1. We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
  2. We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
  3. Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.


Australian Clinical Labs  (ASX:ACL) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) A sufficient margin of safety exists only when the stock is undervalued.

Australian Clinical Labs's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=2.97/2.86
=1.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Australian Clinical Labs GF Value Related Terms

Thank you for viewing the detailed overview of Australian Clinical Labs's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Australian Clinical Labs Business Description

Traded in Other Exchanges
N/A
Address
1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.

Australian Clinical Labs Headlines

No Headlines